These striking differences in neuropathological characteristics indicate that there are likely different disease modifiers of mutant LRRK2 or environmental modifiers that affect neurodegenerative trajectories of α-syn and tau pathology in LRRK2 parkinsonism in vulnerable cell populations. The gene discussed is MAPT; the disease is Parkinsonism.